1. Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease.
- Author
-
Vesa, Cosmin Mihai, Bungau, Simona Gabriela, and Vesa, Cosmin Mihai
- Subjects
Biology, life sciences ,Research & information: general ,ADMET ,GIP ,GLP-1 ,HUVEC ,LY3298176 ,PFK15 synthesis ,SUMMIT ,SURMOUNT ,SURPASS ,SYNERGY ,Tirzepatide ,abietane diterpenoids ,adolescents ,angiogenesis ,cardiovascular medicine ,children ,common carotid artery occlusion ,diabetes ,diabetes mellitus ,dyslipidemia ,ejection fraction ,empagliflozin ,endothelial nitric oxide synthase ,glucagon ,heart failure ,hsa-miR-193b-3p ,hypertension ,incretins ,inflammation ,leptin ,levopimaric acid ,lipid metabolism ,liver ,meta-analysis ,metabolic syndrome ,molecular docking ,morbidity ,mortality ,n/a ,neuroprotection ,nicotinamide mononucleotide ,obesity ,oxidative stress ,peroxisome proliferator activated receptor gamma coactivator 1 alpha ,quinopimaric acid ,retinal ischemia ,retinal ischemia/reperfusion ,sacubitril/valsartan ,sphingolipids ,sphingomyelinase ,statin ,sunitinib L-malate ,synergy ,thromboxane prostanoid receptor ,type 2 diabetes ,type 2 diabetes mellitus ,vasorelaxation ,α-glucosidase - Abstract
Summary: The purpose of this reprint based on the Special issue "Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease", IJMS journal, MDPI, is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease.